Aptose Biosciences Inc. Update - What’s Happening Now

As of May 13, 2026, Aptose Biosciences Inc. has released its financial results for the first quarter of 2026. The company is currently in a transition period while awaiting its acquisition by Hanmi Pharmaceutical.

1. What happened?

Aptose reported its financial performance for the first three months of 2026. The company is currently waiting for its acquisition by Hanmi Pharmaceutical to finalize. While the deal was expected to close sooner, the timeline shifted due to the regulatory review process in South Korea. Both companies now aim to close the deal within May 2026.

2. Why does this matter?

Aptose faces tight cash constraints, holding only $4.1 million in cash as of March 31, 2026. The company has explicitly stated it does not have enough capital to fund operations for the next year. Because of this, Aptose is relying entirely on financial support from Hanmi. Hanmi is providing bridge funding to cover essential costs and keep clinical research running until the deal officially closes.

3. The Current Situation

Aptose is operating in a limited capacity to focus exclusively on the merger and its primary clinical project.

• The Acquisition: Under the agreement, shareholders (excluding Hanmi) will receive C$2.41 per share in cash once the deal closes.
• The Science: The company’s main focus is tuspetinib, an oral drug for patients with relapsed or hard-to-treat acute myeloid leukemia (AML). Aptose is scheduled to present new data on the drug’s safety and effectiveness at the European Hematology Association Congress in June 2026.
• The Cleanup: To save money and focus solely on tuspetinib, Aptose ended its license agreement for luxeptinib and returned all rights to the original owner. This move was designed to cut development costs and align the company’s portfolio with Hanmi’s strategic interests.

4. What should investors know?

• The "Safety Net": Hanmi’s decision to provide bridge funding is a strong signal that they remain committed to the deal. They are essentially paying for the operations of the company they plan to acquire.
• The Price Gap: You may notice Aptose shares trading below the C$2.41 buyout price. This gap typically reflects the market's assessment of the wait time and the inherent risk that regulators might block the deal.
• Risk Remains: The primary risk is that the deal could fall through due to regulatory hurdles in South Korea. If the deal fails, Aptose would face an immediate cash crisis, as it currently lacks the capital to fund its own operations independently.
• Watch the Calendar: Keep a close eye on official regulatory filings for news of final approval in South Korea. This is the final hurdle before the merger can close.

5. What happens next?

Management has two clear goals: meeting the regulatory requirements to close the Hanmi acquisition and preparing clinical data for the EHA Congress in mid-June. Until the deal officially closes, the company will continue to operate under these strict financial limitations.

Bottom Line for Investors: This is essentially a "merger arbitrage" situation. Your investment thesis hinges on whether you believe the South Korean regulatory approval will be granted. If you are considering an entry, ensure you are comfortable with the risk that the deal could collapse, leaving the company in a precarious financial position.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.